NeoGenomics is trading at $16.07 (5.3% up) as investors continue to react to its stronger-than-expected second quarter 2026 earnings and raised full-year guidance.
- The stock is extending gains from its July 29 jump, benefiting from a broad market rally following the July 28 earnings release.
- Shares remain resilient and continue to climb despite general weakness observed across the wider healthcare sector.